---
title: Biomay AG vs Fujifilm Pharmaceuticals U.S.A., Inc
slug_a: biomay
slug_b: fujifilmpharma
site: cdmo
review_signal_gate: closed
canonical_path: /compare/biomay/fujifilmpharma
---

# Biomay AG vs Fujifilm Pharmaceuticals U.S.A., Inc

Side-by-side profile data from each company listing on this directory.

## Biomay AG

- Profile: [/companies/biomay](/companies/biomay)

Biomay AG — GMP CDMO specializing in plasmid DNA, mRNA, and recombinant protein manufacturing from gene construction to market supply, with in-house mRNA lipid-nanoparticle formulation and aseptic fill-finish capabilities.

Services: 8. Modalities: 2. Indications: 0. Locations: 1. Certifications: 1. The strongest documented coverage currently appears in services (8).

### Services

- Recombinant Protein Manufacturing
- Cell-Line Development
- mRNA Manufacturing
- Lipid Nanoparticle (LNP) Formulation
- Sterile Fill-Finish & Aseptic Manufacturing
- Process Development
- CMC Analytical Development
- CMC Regulatory Submission Support

### Modalities

- mRNA
- Gene Therapy

### Development capabilities

- Formulation development

### Manufacturing capabilities

- Drug Substance (DS)
- Drug Product (DP)
- Liquid Vials
- Expression: Mammalian
- Expression: Microbial

## Fujifilm Pharmaceuticals U.S.A., Inc

- Profile: [/companies/fujifilmpharma](/companies/fujifilmpharma)

Fujifilm Pharmaceuticals U.S.A., Inc — CDMO specializing in liposome and lipid nanoparticle (LNP) formulation development and GMP manufacturing from bench to commercial scale, with mRNA process development and aseptic fill-finish capabilities.

Services: 9. Modalities: 2. Indications: 2. Locations: 0. Certifications: 0. The strongest documented coverage currently appears in services (9).

### Services

- Upstream Processing
- Downstream Processing
- mRNA Manufacturing
- Lipid Nanoparticle (LNP) Formulation
- Sterile Fill-Finish & Aseptic Manufacturing
- Process Development
- Formulation Development
- Technology Transfer
- Quality Control Testing

### Modalities

- Oligonucleotide
- mRNA

### Development capabilities

- Formulation development

### Manufacturing capabilities

- Drug Substance (DS)
- Drug Product (DP)
- Liquid Vials